mRNA technology Archives

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

astrazeneca moderna mrna biotech investing

News and Trends 12 Aug 2016

mRNA Money-magnet increases its Pile of Cash to over €1.3Bn

Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership cash to an unbelievable €1.34Bn ($1.5Bn). It can thank AstraZeneca, which is now adding €126M more to its investment. Amid dropping revenues and pipeline cuts, AstraZeneca remains steadily focused on innovation and Biotech. After all, this was the strategy CEO Pascal […]

August 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

mrna astrazeneca cardiometabolic diseases moderna

News and Trends 27 Jul 2016

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

biontech mrna vaccine cancer immunotherapy nature

News and Trends 2 Jun 2016

First All-Cancer mRNA Vaccine that Works Published in Nature

Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a universal cancer vaccine. Originally published on 02/06/2016 BioNTech and its academic partners have published in the well-known publication Nature, describing the first clinically applicable and systemic […]

June 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 May 2016

German mRNA specialist moves into Animal Health in collaboration with Bayer

BioNTech is joining its mRNA technology with Bayer’s expertise in veterinary applications in a new collaboration – to develop first-in-class vaccines for animals. Based in Mainz (Germany), BioNTech is the largest private Biotech in Europe. Along with its CAR-T and TCR programmes, BioNTech is developing mRNA therapies – a promising field in medicine. These include immunotherapies for […]

May 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

News and Trends 14 Nov 2015

What happened this week? mRNA Therapies, TCR & Algae Beer

Monday: Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer Tuesday: What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen! Wednesday: Using Algae and NanoTech to Kill Cancer: An Australian-German Collaboration Thursday (two interviews): Interview: The ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market EU’s Largest Private […]

November 14, 2015 - 1 minutemin - By Philip Hemme

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 12 Nov 2015

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field… We first interviewed Sean Marett, COO of BioNTech. This German Biotech is the largest private Biotech in EU and so far counts over 400 employees…BioNTech also recently signed […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment. CureVac, today announced the official launch of its U.S. operations in […]

September 10, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us